Parametric Portfolio Associates’s Pacira BioSciences PCRX Stock Holding History

Parametric Portfolio Associates’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$18.3M	Buy	239,583 +45,067	+23%	+$3M	0.01%	1011
2021 Q4	$11.7M	Sell	194,516 -3,102	-2%	-$171K	0.01%	1277
2021 Q3	$11.1M	Buy	197,618 +26,429	+15%	+$1.52M	0.01%	1282
2021 Q2	$10.4M	Sell	171,189 -16,383	-9%	-$1.04M	0.01%	1363
2021 Q1	$13.1M	Buy	187,572 +26,924	+17%	+$1.92M	0.01%	1447
2020 Q4	$9.61M	Sell	160,648 -25,667	-14%	-$1.5M	0.01%	1604
2020 Q3	$11.2M	Buy	186,315 +13,499	+8%	+$784K	0.01%	1318
2020 Q2	$9.07M	Buy	172,816 +28,185	+19%	+$1.18M	0.01%	1463
2020 Q1	$4.85M	Sell	144,631 -3,828	-3%	-$159K	﹤0.01%	1753
2019 Q4	$6.72M	Buy	148,459 +45,290	+44%	+$1.92M	﹤0.01%	1829
2019 Q3	$3.93M	Sell	103,169 -3,461	-3%	-$138K	﹤0.01%	2196
2019 Q2	$4.64M	Buy	106,630 +19,567	+22%	+$831K	﹤0.01%	2068
2019 Q1	$3.31M	Sell	87,063 -22,826	-21%	-$891K	﹤0.01%	2290
2018 Q4	$4.73M	Sell	109,889 -589	-0.5%	-$27.5K	﹤0.01%	1940
2018 Q3	$5.43M	Buy	110,478 +26,572	+32%	+$1.15M	﹤0.01%	1961
2018 Q2	$2.69M	Buy	83,906 +11,044	+15%	+$381K	﹤0.01%	2472
2018 Q1	$2.27M	Sell	72,862 -5,893	-7%	-$210K	﹤0.01%	2532
2017 Q4	$3.6M	Sell	78,755 -17,749	-18%	-$703K	﹤0.01%	2167
2017 Q3	$3.62M	Sell	96,504 -13,620	-12%	-$548K	﹤0.01%	2128
2017 Q2	$5.25M	Buy	110,124 +21,880	+25%	+$1.02M	0.01%	1730
2017 Q1	$4.02M	Buy	88,244 +32,009	+57%	+$1.38M	0.01%	1940
2016 Q4	$1.82M	Buy	56,235 +9,864	+21%	+$329K	﹤0.01%	2433
2016 Q3	$1.59M	Buy	46,371 +28,648	+162%	+$1.12M	﹤0.01%	2504
2016 Q2	$598K	Sell	17,723 -4,289	-19%	-$211K	﹤0.01%	3091
2016 Q1	$1.17M	Buy	22,012 +461	+2%	+$27K	﹤0.01%	2815
2015 Q4	$1.66M	Buy	21,551 +4,995	+30%	+$283K	﹤0.01%	2376
2015 Q3	$680K	Sell	16,556 -241	-1%	-$14.8K	﹤0.01%	2564
2015 Q2	$1.19M	Sell	16,797 -5,809	-26%	-$457K	﹤0.01%	2665
2015 Q1	$2.01M	Buy	22,606 +3,363	+17%	+$341K	﹤0.01%	2241
2014 Q4	$1.71M	Sell	19,243 -1,262	-6%	-$119K	﹤0.01%	2333
2014 Q3	$1.99M	Buy	20,505 +16,365	+395%	+$1.59M	﹤0.01%	2079
2014 Q2	$380K	Buy	+4,140	New	+$315K	﹤0.01%	3387

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Parametric Portfolio Associates's PCRX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Pacira BioSciences (PCRX) stake by 23% in Q1 2022, buying an estimated $3M and bringing the position to 239,583 shares worth $18.3M. The position accounts for 0.01% of the portfolio, ranked #1011.

Parametric Portfolio Associates first reported a position in PCRX in Q2 2014 and has held it in 32 quarters since. 301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

Parametric Portfolio Associates held 239,583 shares of Pacira BioSciences worth $18.3M as of Q1 2022.
Parametric Portfolio Associates bought 45,067 Pacira BioSciences shares in Q1 2022, an estimated $3M.
Pacira BioSciences made up 0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1011 holding.
Parametric Portfolio Associates first reported a position in Pacira BioSciences in Q2 2014 and has held it in 32 quarters since.
301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.